AI drug development
They will collaborate on identifying novel therapeutic drug candidates for lung cancer.
The company will use the funds to accelerate its growth, expand the use of its models for different conditions and open an office in Cambridge.
Xaira's CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab's scientific papers.
TenAces will develop an AI platform to help identify protein interactions that naturally occur in the body to assist with targeted protein degradation.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.
The company's computational solution uses AI, modeling and data analysis of naturally occurring proteins to generate superior antibodies, enzymes and vaccine immunogens.
The round brings the company's total raise to $93 million.
The multinational pharma company will access Tempus' AI-enabled data library to further therapeutic development and advance its portfolio in oncology.